Asterias Biotherapeutics — Merger or Acquisition (December 2018)
22 slides from Asterias Biotherapeutics's merger presentation, Dec 4, 2018
Slide 1: Asterias Biotherapeutics – Clinical-Stage Immunotherapy and Neurology Company
Clinical-Stage Immunotherapy and Neurology Company Asterias BiotherapeuticsNYSE Market: ASTDecember 2018 Filed by Asterias Biotherapeutics, Inc.Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of theSecurities Exchange Act of 1934 Subject Corporation: As
Slide 2: Forward-Looking Statements
2 Statements pertaining to future financial and/or operating and/or clinical research results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects express
Slide 3: Announced Transaction with BioTime, Inc.
3 On November 8, 2018, Asterias announced it had entered into an Agreement and Plan of Merger with BioTime, Inc. (NYSE MKT: BTX)BioTime previously owned approximately 39% of AsteriasStock merger with fixed exchange ratioEach AST share to convert into 0.71 shares of BTXCombined company to be run by B
Slide 4: Neurology and immunotherapy platforms in the clinic
4 Asterias’ neurology platform is in the clinic with a Phase 1/2a clinical trial evaluating OPC1 in the treatment of severe cervical spinal cord injury (SCI)Significant pre-clinical data supporting clinical developmentClinical data showing positive safety profile, durable cell engraftment at the inj
Slide 5: Clinical Programs – Development Pipeline
5 PROGRAM Partners/Funding PRECLIN PHASE 1 PHASE 2 PHASE 3Programs with Ongoing Clinical Studies AST-OPC1Spinal Cord Injury (subacute) AST-VAC2Lung Cancer Allogeneic Other Clinical Programs AST-VAC1Leukemia (AML) Autologous Phase 1/2a study enrolled; final data readout in Q1 2019 Positive phase 2 da
Slide 6: Spinal Cord Injury Program
Spinal Cord Injury Program
Slide 7: AST-OPC1: Introduction
AST-OPC1 is a cellular therapy utilizing oligodendrocyte progenitor cells (OPCs)OPCs are found in the human body and are precursors to oligodendrocyte cells which, among other things, provide electrical insulation for nerve axons in the form of a myelin sheathAST-OPC1 administers OPCs into the body
Slide 8: AST-OPC1 Potential Mechanisms of Action
AST-OPC1 Potential Mechanisms of Action Secretes neurotrophic factors Promote increased neurite outgrowth Myelination of axons Rag2-/- γc-/- /shi mouse + AST-OPC1 Control Media AST-OPC1 CM shiverer mouse shi mouse + AST-OPC1 TubIII Prevents Cavitation Control AST-OPC1 8
Slide 9: AST-OPC1 in Spinal Cord Injury (SCI)
Significant unmet medical need for patients with severe SCIThe therapeutic goal for AST-OPC1 is to help restore arm, hand and finger function in SCI patients thereby increasing their independence and quality of lifeSignificant lifetime direct healthcare costs; can reach $5 million for a patientVery
Slide 10: Potential to Have Clinically Meaningful Benefit
Potential to Have Clinically Meaningful Benefit Capability C1-C3 C4 C5 C6 C7-C8 Bowel Bladder Bed Mobility Transfers Pressure Relief Eating Dressing Grooming Bathing Wheelchair Car Transport Daily Home Care 24 hr Attendant 18-24 hr Attendant 6-12 hr Assistance 4 hr Housework 1 hr Housework Steeves e
Slide 11: Pre-Clinical and Clinical Evidence Supporting OPC1 in SCI
Survives in the Spinal CordGreatest Activity in Subacute InjuryImproves Locomotor ActivityReduces Parenchymal CavitationMigrates Up 5cm in Spinal CordNo Distribution Outside CNSDoes Not Increase MortalityDoes Not Induce Systemic ToxicityDoes Not Produce TeratomasProduces Low Frequency (1-2%) Small E
Slide 12: OPC1 Clinical Data from Phase 1/2a study
To date, there have been no serious adverse events (SAEs) related to the OPC1 cellsThere have been no serious, unexpected, adverse events related to OPC1, the injection procedure, or the drug used for immunosuppressionSafety profile includes long- term follow up of Phase 1 safety study subjects thro
Slide 13: RMAT Designation
FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation for AST-OPC1The RMAT designation is granted to regenerative medicine therapies for which “preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs” for a “serious or life-threa
Slide 14: Immunotherapy Platform
Immunotherapy Platform
Slide 15: Early Successes in Cancer Immunotherapy Have Improved Treatment But More is Needed
15 Early Successes in Cancer Immunotherapy Have Improved Cancer Treatment in Recent Years But More is Needed VAC2 PlatformStimulate T cell response through natural antigen presentation mechanismLess potent initial immunity; best suited for MRD and combination approachesApplicable to wide range of an
Slide 16: AST-VAC2 Immunotherapy Program: Introduction
Our VAC2 program uses dendritic cells to stimulate an immune response to telomerase, a universal cancer antigenThe LAMP signal sequence is also used to optimize immune response through stimulation of both CD8+ cytotoxic and CD4+ helper T cell responsesAST-VAC2 allogeneic dendritic cells are manufact
Slide 17: VAC1 Phase 2 Study Results in AML
20-40% 10-20% 58% All patients in CR (N=19) 57% >60 years old (N=7) Relapse free survival at 52 months% of patients AST-VAC1Historical 17 Proprietary and Confidential Information VAC1 Phase 2 Study Results in AML VAC1 Phase 2 trial highlights Multicenter, open-label studyIncluded only intermediate a
Slide 18: VAC2 Builds on VAC1 POC With An Allogeneic Dendritic Cell Product
VAC2 Builds on VAC1 POC With An Allogeneic Dendritic Cell Product Product to be supplied from a single master cell bank, allowing scalability/consistencyThousands of patient treatments can be manufactured in a single batchCryopreserved product available ‘off-the-shelf’ on demand Culture Electroporat
Slide 19: VAC2 Phase 1 Study Underway
VAC2 Phase 1 Study Underway Patient Population Patients with NSCLC 12 PatientsDose 1x107 AST-VAC26 Doses id. HLA A2 Typing 2 Year Follow- up for Responses/ Relapse Control ARM HLA-A2-Patients with Advanced Disease 12 PatientsNo Vaccine 12 PatientsDose 1x107 AST-VAC26 Doses id. Control ARM HLA-A2- Pa
Slide 20: Cancer Research UK Partnership to Execute VAC2 Clinical Trial in NSCLC
Cancer Research UK Partnership to Execute VAC2 Clinical Trial in NSCLC to Establish Safety of Allogeneic Approach and Enable Other VAC2 Studies Asterias Performed Development and Transfer of Clinical AST-VAC2 Manufacturing ProcessCRUK Responsibilities:Execute cGMP Manufacture of AST-VAC2 for Clinica
Slide 21: VAC2 Platform has Broad Potential Beyond Current Areas of Focus
VAC2 Platform has Broad Potential For Application Beyond Current Areas of Focus Monotherapy in MRD Setting With High Risk of Relapse Approach: Rationale: Stimulate T cell response to ‘seek and destroy’ residual cancer stem cells after debulking chemotherapy, surgery, radiotherapyPromising results fr
Slide 22: Potential Future Milestones
22 Potential Future Milestones 2019 2020 2021 2022 2023 OPC1 12 month Top-Line Data Updatefrom Phase 1/2a studyFDA Clearance on next study designCIRM Grant Award for next study Publication on Phase 1/2a study FPI for Phase 2B RCTPhase 2B Enrollment Updates Phase 2B EnrollmentUpdates Enrollmentcomple
Asterias Biotherapeutics — Merger or Acquisition (December 2018) on 6ix